Literature DB >> 20887870

Genetic mouse models of Parkinson's disease The state of the art.

Iddo Magen1, Marie-Françoise Chesselet.   

Abstract

The identification of several mutations causing familial forms of Parkinson's disease (PD) has led to the creation of multiple lines of mice expressing similar genetic alterations. These models present a unique opportunity for understanding pathophysiological mechanisms leading to PD in a mammalian brain and provide models that are suitable for the preclinical testing of new therapies. Different lines of mice recapitulate the symptoms and pathological features of PD to various extents. This chapter examines their respective advantages and highlights some of the key findings that have already emerged from the analysis of these new models of PD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20887870     DOI: 10.1016/S0079-6123(10)84004-X

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  52 in total

1.  Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Alicia M Pickrell; Milena Pinto; Aline Hida; Carlos T Moraes
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 2.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 3.  Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model.

Authors:  L David Willison; Takashi Kudo; Dawn H Loh; Dika Kuljis; Christopher S Colwell
Journal:  Exp Neurol       Date:  2013-01-24       Impact factor: 5.330

4.  In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy.

Authors:  Lidia Reznichenko; Qun Cheng; Krystal Nizar; Sergey L Gratiy; Payam A Saisan; Edward M Rockenstein; Tanya González; Christina Patrick; Brian Spencer; Paula Desplats; Anders M Dale; Anna Devor; Eliezer Masliah
Journal:  J Neurosci       Date:  2012-07-18       Impact factor: 6.167

Review 5.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

6.  Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.

Authors:  Hoa A Lam; Nanping Wu; Ingrid Cely; Rachel L Kelly; Sindalana Hean; Franziska Richter; Iddo Magen; Carlos Cepeda; Larry C Ackerson; Wendy Walwyn; Eliezer Masliah; Marie-Françoise Chesselet; Michael S Levine; Nigel T Maidment
Journal:  J Neurosci Res       Date:  2011-04-12       Impact factor: 4.164

Review 7.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

Review 8.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

9.  Site-specific differences in proteasome-dependent degradation of monoubiquitinated α-synuclein.

Authors:  Tharindumala Abeywardana; Yu Hsuan Lin; Ruth Rott; Simone Engelender; Matthew R Pratt
Journal:  Chem Biol       Date:  2013-10-24

10.  Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Authors:  Dora Games; Peter Seubert; Edward Rockenstein; Christina Patrick; Margarita Trejo; Kiren Ubhi; Benjamin Ettle; Majid Ghassemiam; Robin Barbour; Dale Schenk; Silke Nuber; Eliezer Masliah
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.